Plain-English translation of NCT05698901 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Fabry disease is a rare genetic condition where the body can't break down certain fats, which then build up in organs like the heart, kidneys, and brain. This study is examining whether specific blood tests (measuring substances like Lyso-Gb3, NT-proBNP, and cardiac troponin) along with heart imaging scans can better help doctors understand how the disease affects the heart and whether the medication is working effectively.
Right now, doctors don't have a clear way to measure which blood tests and imaging methods best show how Fabry disease damages the heart or how well the medication is helping. This study will gather that information so doctors can better track patients' progress and make better treatment decisions.
You likely qualify if…
You likely don't qualify if…
You will be placed into one of two groups: either patients newly starting treatment or those already on . Over the course of the study, you will have regular clinic visits where you'll provide blood samples (to measure the disease biomarkers) and undergo heart imaging and electrical tests (like ECG and ultrasound) to track how your heart is being affected. The study follows your progress to see how these tests and blood markers relate to your heart health and how well the medication is working for you.
AI-generated summary from trial data · Aug 3, 2026 · Not medical advice
Taiwan